Key PointsQuestionWhat are the risks of hypophosphatemia following iron replacement with iron isomaltoside 1000 (now called ferric derisomaltose) vs ferric carboxymaltose? FindingsIn 2 randomized trials of 245 total patients (trial A: n = 123; trial B: n = 122) with iron-deficiency anemia, who were intolerant to or unresponsive to oral iron, the incidence of hypophosphatemia with use of iron isomaltoside, compared with ferric carboxymaltose, was 7.9% vs 75.0% in trial A and 8.1% vs 73.7% in trial B over 35 days; both differences were statistically significant. MeaningIron isomaltoside, compared with ferric carboxymaltose, resulted in lower incidence of hypophosphatemia, but further research is needed to determine the clinical importance of these findings.
JAMA – American Medical Association
Published: Feb 4, 2020